Lymphocyte-depleted classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group

Journal of Clinical Oncology

Volumn 29, Issue 29, 2011, Pages 3914-3920

  Klimm, Beate ^a   Franklin, Jeremy ^b   Stein, Harald ^c   Eichenauer, Dennis A ^a   Haverkamp, Heinz ^a   Diehl, Volker ^a   Fuchs, Michael ^a   Borchmann, Peter ^a   Engert, Andreas ^a  

^a German Hodgkin Study Group   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Pathodiagnostik Berlin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; GERMANY; HODGKIN DISEASE; HUMAN; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BIOPSY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053949830     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.4703     Document Type: Article

References (33)

1. Swerdlow SH, Campo E, Harris NL, et al: WHO classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France, International Agency for Research on Cancer, 2008
2. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al: Lymphocyte-rich classical Hodgkin's lymphoma: Clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol 23:5739-5745, 2005
3. Nogová L, Reineke T, Brillant C, et al: Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434-439, 2008 (Pubitemid 351171696)
4. Mani H, Jaffe ES: Hodgkin lymphoma: An update on its biology with new insights into classification. Clin Lymphoma Myeloma 9:206-216, 2009
5. Pileri SA, Ascani S, Leoncini L, et al: Hodgkin's lymphoma: The pathologist's viewpoint. J Clin Pathol 55:162-176, 2002 (Pubitemid 34250900)
6. Slack GW, Ferry JA, Hasserjian RP, et al: Lymphocyte depleted Hodgkin lymphoma: An evaluation with immunophenotyping and genetic analysis. Leuk Lymphoma 50:937-943, 2009
7. Hasenclever D: The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 13:75-78, 2002 (suppl 1)
8. Allemani C, Sant M, De Angelis R, et al: Hodgkin disease survival in Europe and the U.S.: Prognostic significance of morphologic groups. Cancer 107:352-360, 2006
9. Dühmke E, Franklin J, Pfreundschuh M, et al: Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905-2914, 2001 (Pubitemid 32538201)
10. Sieber M, Tesch H, Pfistner B, et al: Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediatestage Hodgkin's lymphoma: Final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 20:476-484, 2002 (Pubitemid 34072532)
11. Sieber M, Tesch H, Pfistner B, et al: Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: Final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 15:276-282, 2004 (Pubitemid 38262628)
12. Engert A, Franklin J, Eich HT, et al: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 25:3495-3502, 2007 (Pubitemid 47310889)
13. Engert A, Schiller P, Josting A, et al: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's Lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003 (Pubitemid 46594052)
14. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 (Pubitemid 36682817)
15. Engert A, Pluetschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
16. Eich HT, Diehl V, Görgen H, et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206, 2010
17. Borchmann P, Haverkamp H, Diehl V, et al: Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). J Clin Oncol doi: 10.1200/JCO.2010.33.9549
18. Borchmann P, Topp MS, Behringer K, et al: Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin Lymphoma: Results of the second interim analysis of the GHSG HD13 trial. Onkologie 33:V448, 2010 (suppl 6)
19. Engert A, Borchmann P, Pluetschow A, et al: Dose-escalation with BEACOPP escalated is superior to ABVD in the combined-modality treatment of early unfavorable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood 116:765a, 2010 (abstr)
20. Engert A, Kobe C, Markova J, et al: Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin lymphoma after completion of chemotherapy: Final report of the GHSG HD15 Trial. Blood 116:764a, 2010 (abstr)
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
23. Hasenclever D, Diehl V: Prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
24. Benharroch D, Levy A, Gopas J, et al: Lymphocyte-depleted classic Hodgkin lymphoma: A neglected entity? Virchows Arch 453:611-616, 2008
25. Miller TP, Byrne GE, Jones SE: Mistaken clinical and pathologic diagnoses of Hodgkin's disease: A Southwest Oncology Group study. Cancer Treat Rep 66:645-651, 1982 (Pubitemid 12129348)
26. Kant JA, Hubbard SM, Longo DL, et al: The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease. J Clin Oncol 4:284-294, 1986 (Pubitemid 16133081)
27. Riddell S, Weinerman B, Kemel S, et al: The treatment resistance of lymphocyte depleted Hodgkin's disease. Cancer 46:1503-1508, 1980 (Pubitemid 11253543)
28. Greer JP, Kinney MC, Cousar JB, et al: Lymphocyte-depleted Hodgkin's disease: Clinicopathologic review of 25 patients. Am J Med 81:208-214, 1986 (Pubitemid 16018858)
29. Mauch P, Greenberg H, Lewin A, et al: Prognostic factors in patients with subdiaphragmatic Hodgkin's disease. Hematol Oncol 1:205-214, 1983 (Pubitemid 13024676)
30. von Wasielewski R, Seth S, Franklin J, et al: Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 95:1207-1213, 2000 (Pubitemid 30099828)
31. Klimm B, Diehl V, Engert A: Hodgkin's lymphoma in the elderly: A different disease in patients over 60. Oncology (Williston Park) 21:982-990, 2007 (Pubitemid 47106312)
32. Ballova V, Rüffer JU, Haverkamp H, et al: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16:124-131, 2005
33. Halbsguth TV, Nogová L, Mueller H, et al: Phase 2 study of BACOPP (bleomycin, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG). Blood 116:2026-2032, 2010